Anticonvulsant Market for Fibromyalgia - Global Industry Analysis, Size, Share, Trends, Analysis, Growth, and Forecast 2017 - 2025
Anticonvulsant Market for Fibromyalgia: Snapshot
Anticonvulsant are pharmacological agents from a diverse group that are used for the treatment of epileptic seizures. Anticonvulsants are increasingly in demand on account of their use for the treatment of bipolar disorders. They are also used for the treatment of borderline personality disorder. Anticonvulsants act as stabilizers of mood and helps in the treatment of neuropathic pain. They suppress the rapid, excessive firing of neurons when a person gets seizures. Anticonvulsants also keep the seizure within the brain from spreading to other areas. Anticonvulsants are used extensively for the treatment of fibromyalgia and are thus, expected to be in continued demand during the period from 2017 to 2025. The growing incidences of epilepsy and need for managing pain due to migraines, and rising cases of fibromyalgia worldwide will boost the global anticonvulsant market for fibromyalgia in the coming years.
The report takes into account all the leading factors boosting the growth of the anticonvulsant market. It also studies the definition, causes, prevention methods, and treatment options that are available for fibromyalgia. Fibromyalgia causes pain all over the body. The patient also experiences tender points in different parts of the body such as neck, back, hips, arms, shoulders, and legs, when pressure is applied. Thus, the need for effective treatment options for the treatment of this painful disorder will boost the growth of the global anticonvulsant market for fibromyalgia in the coming years.
Global Anticonvulsant Market for Fibromyalgia: Overview
The global anticonvulsant market used for fibromyalgia demonstrates a massive potential for future growth. The efficiency of anticonvulsants in the treatment of various neurological disorders, specifically fibromyalgia, is likely to increase their popularity, reflecting greatly on their demand over the forthcoming years.
The increasing prevalence of fibromyalgia, boosted substantially by the ever-rising base of geriatric population and the increasing expenditure on healthcare, thanks to the augmented disposable income of people have been acting as the key factors driving this market and are expected to maintain its growth pace in the near future too.
Global Anticonvulsant Market for Fibromyalgia: Drivers and Restrains
Currently, a number of both, patented and off-label anticonvulsant drugs, are being used in the treatment of fibromyalgia. Although with expired patents, Topiramate, levetiracetam, divalproex sodium, lamotrigine, oxcarbazepine, and carbamazepine are driving the global market for anticonvulsants used for the treatment of fibromyalgia considerably. In addition, a robust pipeline of anticonvulsants drugs is waiting for U.S. FDA approval, which, post approval, is expected to add significantly to this market in the years to come. The rising preference for generic products is also projected to influence anticonvulsant market remarkably over the next few years.
On the other hand, the stringent regulatory guidelines for the approval of drugs may create obstacles in the growth trajectory of this market to some extent. However, the advancement in medical and healthcare infrastructure in emerging economies is likely to normalize their effects on this market in the near future.
Global Anticonvulsant Market for Fibromyalgia: Geographical Analysis
The global market for anticonvulsant used for fibromyalgia registers its presence across Asia Pacific, Europe, North America, and the Rest of the World. Due to the presence of a large pool of established players, North America has acquired the leading position in this market. The high disposable income of consumers that enables them to afford expensive treatments, is likely to maintain the growth pace of the North America market for anticonvulsants for fibromyalgia over the next few years. Apart from this, the growing awareness among consumers regarding health and wellness and the rising number of neurological disorders are also expected to further drive this market.
Asia Pacific, on the other hand, is anticipated to offer the most promising opportunities for the growth of the worldwide anticonvulsant market used for fibromyalgia in the near future. The improvement in economic conditions, rise in purchasing power, and the increase in the living standard of people in Asian countries, such as India and China, are likely to boost this regional market over the years to come. The substantial progress in the medical tourism industry in this region is also projected to reflect positively on the demand for anticonvulsants in Asia Pacific in the near future.
Global Anticonvulsant Market for Fibromyalgia: Companies Mentioned in the Report
Pfizer Inc., GlaxoSmithKline Inc., UCB Group, Novartis AG, Johnson & Johnson (J&J), and Abbott Laboratories are some of the leading players operating in the global market for anticonvulsants used for fibromyalgia.
The study presents reliable qualitative and quantitative insights into:
The regional analysis covers:
The vast market research data included in the study is the result of extensive primary and secondary research activities. Surveys, personal interviews, and inputs from industry experts form the crux of primary research activities and data collected from trade journals, industry databases, and reputable paid sources form the basis of secondary research. The report also includes a detailed qualitative and quantitative analysis of the market, with the help of information collected from market participants operating across key sectors of the market value chain. A separate analysis of macro- and micro-economic aspects, regulations, and trends influencing the overall development of the market is also included in the report.
Highlights of the report:
Note: Immense care has been taken to present data with the highest levels of accuracy in all TMRResearch reports. Nevertheless, recent developments related to market/vendor landscape may take time to reflect in the analysis.
Flat 10% discount on Single User License if you prebook this report
Flat 10% discount on Multiple User License if you prebook this report
Flat 10% discount on Corporate License if you prebook this report